The effects of recombinant human growth hormone (rhGH) supplementation on adipokines and C-reactive protein in obese subjects

摘要: Abstract Objective Obese subjects have functional growth hormone deficiency (GHD). Recombinant human GH (rhGH) treatment of pituitary GHD improves serum levels leptin, adiponectin and C-reactive protein (CRP). This study was undertaken to determine whether these rhGH-induced changes occur in obese during rhGH supplementation. Design Randomized double-blind placebo-controlled trial low-dose (200μg/day for the first month, then 400μg/day men 600μg/day women thereafter) or placebo supplementation as an adjuvant a standard weight loss program. Subjects Forty healthy subjects, 28 premenopausal menstruating (35±7 SD years) 12 (37±6years). Measurements Body weight, BMI, body composition (assessed by dual energy X-ray absorptiometry [DEXA]), glucose, insulin, IGF-I, IGFBP-3, insulin resistance index (homeostasis modal assessment [HOMA]), CRP were performed at baseline 6months. Results For similar entry BMI values, when compared with had higher percent fat (BF) (43.5±4.6% vs. 29.8±4.0%, p =0.04). Serum leptin CRP, but not adiponectin, correlated significantly BF both sexes. increased IGF-I Z-Score between 6months (from −0.7±0.9 0.1±1.1 SD, =0.01) modestly decreased 38.4±7.8% 35.6±7.5%, =0.046). Despite there no differences regard adiponectin. Conclusion It is concluded that obesity, although increases reduces fat, lack significant suggests does effect on markers adiposity.